Repeat dose oral toxicity studies were conducted in rat and dog to assess the safety for human clinical testing of the potent dopamine D3 receptor antagonist, PNU-177864. Systemic phospholipidosis was the principal treatment-related change with epididymal epithelial cell phospholipidosis being the most prominent finding in rats and dogs. Epididymal epithelial cells had no histologic evidence of degeneration; sperm density and morphology were normal histologically in both species; and sperm concentration, morphology, and motility in the dog were comparable to dogs given vehicle. Other sites with phospholipidosis included lymphoid tissues (lymph nodes, Peyer's patches, and/or spleen), pulmonary alveolar macrophages, and peripheral blood lymphocytes in rats and dogs and adrenal cortex, liver, pituitary, hair follicles, bone marrow lymphocytes and plasma cells, and skeletal muscle in rats only. The phospholipidosis was resolved after a 6-week recovery period in all tissues but epididymis. There was no evidence of cell injury in tissues that had phospholipid accumulations except in rat skeletal muscle that had multifocal myofiber degeneration and necrosis. For clinical trials, serum AST and CK and peripheral blood lymphocyte vacuolation were considered potential safety biomarkers for skeletal muscle degeneration and phospholipidosis, respectively.
INTRODUCTION
A group of structurally and pharmacologically diverse compounds, known collectively as cationic amphiphilic drugs (CAD), cause the accumulation of phospholipids in lysosomes of affected cells. More than 50 CADs have induced phopholipidosis in animals, humans, and in in vitro cell cultures (Reasor, 1989; Halliwell, 1997) . CADs derive their designation from a common physicochemical property, a hydrophilic portion containing a primary or substituted nitrogen group that is charged at physiological pH and a hydrophobic portion consisting of an aromatic and/or aliphatic ring structure often substituted with one or more halogen atoms. CADs produce their effects by directly interacting with intracellular phospholipids or altering the synthesis and metabolism of phospholipids (Hostetler, 1984; Reasor, 1989; Halliwell, 1997) . The morphologic hallmark of the cellular accumulation of phospholipids is the presence of lysosomal lamellar bodies (LLB), which are secondary lysosomes filled with electron-dense, membranous, lamellar material (Reasor, 1989; Halliwell, 1997) .
Phospholipidosis occurs in almost any tissue and its tissue distribution can be quite different between animal species (Reasor, 1989; Halliwell, 1997) . Massive accumulations can occur in animal tissues such as the lung with little effect on organ function (Riva et al., 1987; Reasor, 1989; Halliwell, 1997) . Even when there are clear adverse effects in tissues with phospholipidosis, investigators have been unable to establish the causative relationship between phospholipidosis and the untoward effect(s) making the human risk assessment for CADs challenging. For these reasons, the assessment of potential target organ dysfunction and the identification of clinical biomarkers are important objectives for preclinical toxicology studies.
The safety of PNU-177864, a dopamine D3 receptor antagonist, was evaluated in rats and dogs in preliminary 2-week and Good Laboratory Practices (GLP)-regulated 4-week toxicology studies. PNU-177864 is structurally consistent with a CAD and produced systemic phospholipidosis in rats and dogs with an unusual affinity for epididymis, pituitary, peripheral blood lymphocytes, and hair follicles, sites rarely or not reported in the literature. The changes in these and other tissues were characterized morphologically and functional endpoints for the epididymal changes and potential biomarkers for the toxicologic findings were investigated.
MATERIALS AND METHODS
Compound and Dosing Formulations: PNU-177864 ( Figure 1 ) was dosed as a hydrochloride salt and dissolved in 0.3 M citric acid buffer adjusted to pH 2.7.
Animals: Eight-to 9-week-old male and female Sprague-Dawley rats [Cr1:CD(SD)BR] (Charles River Laboratories, Portage, MI) or 9-10-month-old beagle dogs (Marshall Farms, NY) were housed in individual cages (rats) or runs (dogs) in an AALAC-accredited facility in environmentally controlled rooms (20 ± 2
• C, 49% to 61% relative humidity, 12-hour light/12-hour dark cycle). Rodent laboratory chow (No. 5002, Purina Mills, Inc., St. Louis, MO) were allowed at least 1 week for acclimation to the animal facilities and diet before being used in any experiment. The Institutional Animal Care and Use Committee of Pharmacia & Upjohn approved all experimental protocols.
Study Design
Toxicology and Biomarker Studies: Groups of rats received PNU-177864 orally via gastric gavage, once daily, at doses of 0 (vehicle only), 12.5, 50, or 200 mg/kg/day for 2 weeks (5/sex/group) or 0 (vehicle only), 8, 25, or 80 mg/kg/day for 4 weeks (15/sex/group). At the completion of the dosing phase of the 4-week study, the last 5/sex/group entered a 6-week recovery period. For dogs, groups were dosed once daily with 0, 2, 10, and 50 mg/kg/day for 2 weeks (2/sex/group) or 0, 0.5, 4, and 32 mg/kg/day for 4 weeks (6/sex/group). In the latter study, the last 2 animals/sex/group entered a 6-week recovery period after the 4 week dosing phase.
Doses selected for the 2-week studies were based on acute tolerability studies in rats and dogs and were expected to produce a range of toxicity to facilitate dose selection for the definitive 4-week GLP studies. High doses for the rat (200 mg/kg/day) and dog (50 mg/kg/day) 2-week studies exceeded the maximal tolerated dose (MTD) based on mortality in the rat and seizures in the dog. The high doses chosen for the rat and dog 4-week studies were expected to approximate the MTD and the low and mid doses were selected to examine the dose-toxicity relationship and establish a noobserved-adverse-effect level (NOAEL).
Rat and dog 4-week studies were done according to GLP. For both rats and dogs, all animals were necropsied, gross observations were recorded, selected organs were weighed, and tissues were saved for histologic examination. Additional sections of liver and epididymis were collected from dogs at the conclusion of the 4-week study and saved for electron microscopic examination. Peripheral blood smears were collected from rats and dogs and lymphocyte morphology was evaluated microscopically. Bone marrow smears were prepared at the time of necropsy from the femoral (rat) or rib (dog) bone marrow. All tissues collected at necropsy were fixed in 10% neutral buffered formalin excepting testes, which were placed in Bouin's fixative, and eyes, which were placed in Davidson's fixative. Tissues collected for electron microscopy were placed in 3% glutaraldehyde. Bone marrow smears were fixed in methanol.
Hematoxylin and eosin-stained tissues from rats and dogs were evaluated by light microscopy. The light microscopic observation of increased cytoplasmic foamy vacuolation was used to make a preliminary diagnosis of phospholipidosis in tissues. In lymphocytes and plasma cells of bone marrow smears, and in peripheral blood lymphocytes, the diagnosis of phospholipidosis was based on the light microscopic finding of one to few large, clear, cytoplasmic vacuoles. For most tissues (liver and epididymis from both dog and rat; adrenal gland, lung, pituitary, biceps femoris, and mesenteric lymph node from rat) the light microscopic diagnosis was confirmed by the electron microscopic identification of lysosomal lamellar bodies (LLB), secondary lysosomes filled with electron-dense, membranous, lamellar material.
Dog Sperm Evaluation
To evaluate the effect of PNU-177864 on sperm morphology, motility, and number in dogs, the left epididymis was removed at necropsy and sperm were collected from the caudal portion of the epididymis from all dosing phase dogs in the 4-week GLP study. Percent motile (viable) sperm was determined visually, using a hemocytometer, on sperm samples obtained from the distal segment of the left vas deferens. Sperm concentration was determined from samples obtained from the left caudal epididymis; these were weighed and frozen on the day of necropsy for subsequent examination. The vas deferens sample preparation used for motility evaluation was also used for the morphology evaluation following formalin fixation and staining with eosin. Morphological endpoints were based primarily on head and tail abnormalities according to a modification of the classification systems described previously (Linder et al., 1992; Seed et al., 1996) .
Rat Electron Microscopy Study
In an additional rat study, groups of 10 male rats received PNU-177864 orally via gastric gavage, once daily, at doses of 0 (vehicle only) or 200 mg/kg/day for 9 days. On Days 3, 6, and 8 of the study, biceps femoris muscle was collected for light and electron microscopy from 2 rats in each group. On Day 9, biceps femoris muscle, pituitary, lung, epididymis (caput, corpus, and cauda), adrenal gland, liver, and mesenteric lymph node were collected for light and electron microscopy. Triceps muscle was collected for light microscopy only. Tissues were collected following whole body perfusion with 1.5% glutaraldehyde fixative. Briefly, rats were deeply anesthetized by inhalation of methoxyflurane followed by intraperitoneal injection of urethane (500 mg/mL, 0.2 mL/100 g body weight). The entire body was perfused with 1.5% glutaraldehyde via a blunt needle passed through the left ventricle of the heart into the aortic arch. The fixative was prewarmed to approximately 37
• C and injected with a peristaltic pump set to a flow rate of approximately 50 mL/min to assist perfusion. The cranial vena cava or right atrium of the heart was opened to allow for the exit of blood and fixative. After completion of perfusion, tissue samples for light microscopy were placed in 10% neutral buffered formalin. Those for electron microscopy were placed in 3% glutaraldehyde.
Light and Electron Microscopy
Tissues collected for light microscopy were dehydrated in ethanol, cleared in xylene, and embedded in paraffin. Sections were cut at 5 µm, stained with hematoxylin-phloxine-eosin, and examined by routine light microscopy. Bone marrow smears were stained with Wright's stain. Tissues collected for transmission electron microscopy were quickly removed TOXICOLOGIC PATHOLOGY from the animals, placed in cold (wet ice) 3% electron microscopy grade glutaraldehyde in a 0.1 M phosphate buffer at pH 7.3, and minced to less than 1-mm 3 pieces. The minced specimens were placed in fixative-filled 20-ml glass scintillation vials on wet ice for 1-2 hours, washed twice in buffer, and secondarily fixed in buffered 1% osmium tetroxide for 1 hour at room temperature. The samples were dehydrated in a graded ethanol series, embedded in Polybed 812 (Polysciences, Inc., Warrington, PA) epoxy resin, and thin-sectioned in preparation for transmission electron microscopy. Sections were placed on 200 mesh copper grids and stained with 5% methanolic uranyl acetate and Reynolds' lead citrate. Ultrastructural observations were performed on a JEOL 1230 TEM at 80 kV. Micrography was done on 4489 EM film and printed to Kodachrome II RC F3 paper (Eastman Kodak Company, Rochester, NY).
RESULTS

Distribution of Phospholipidosis in Rats and Dogs Given PNU-177864
Light microscopic changes characteristic of phospholipidosis were observed in multiple tissues in rats and dogs (Table 1) . Epididymal changes were most prominent in both species. Both rats and dogs had changes consistent with phospholipidosis in lymphoid tissues (foamy macrophages in lymph nodes, white pulp of the spleen, or in Peyer's patches), pulmonary alveolar macrophages, epididymal epithelial cells, and peripheral blood lymphocytes. Rats also had phospholipidosis in the lymphocytes and plasma cells of the (Figures 2-4) . In some cases (hepatocytes, macrophages, adrenal cortical cells), the target cells were slightly swollen. The distribution in the target tissues was generally diffuse; however, in the rat and dog epididymis, the body of the epididymis had the most prominent changes and, in the rat pituitary, the vacuolation was more easily observed in acidophils although other cell types were also affected. The increased vacuolation was not associated with any histologic evidence of cell injury in any of the target tissues with the exception of skeletal myocytes. Myocytes that contained vacuoles were frequently fragmented and the sarcoplasm was hyalinized. Collections of macrophages with intracytoplasmic cell debris were observed in some of these degenerate fibers.
Electron microscopy was done on numerous tissues from both rats and dogs. Multilamellar, whorled material consistent with laminated lamellar bodies (LLB) were demonstrated in secondary lysosomes of hepatocytes, macrophages (mesenteric lymph node and lung), adrenal cortical epithelial cells, pituitary epithelial cells, endothelial cells of multiple tissues, and skeletal myocytes of the rat and in the epididymal epithelial cells of both rats and dogs (Figures 2 and 3) . The presence of LLBs in these cell types was diagnostic of phospholipidosis.
After 4 weeks of dosing with PNU-177864, rats and dogs were placed on a 6-week recovery period. Tissues with lesions consistent with phospholipidosis (Table 1) were evaluated from the recovery phase animals. With the exception of the epididymis, histologic and electron micrographic evidence of phospholipidosis was absent after the recovery period. The epididymis of 1 of 5 high-dose rats had minimal epithelial vacuolation and electron micrographs of dog epididymis demonstrated increased numbers of LLBs compared to controls.
Epididymal Phospholipidosis Did Not Result in Sperm Abnormalities in the Dog
Epididymal phospholipidosis was the most frequent and prominent finding in both species and was the change that defined the no-observed-effect level (NOEL) for dogs (0.5 mg/kg/day). The epididymal histologic changes were more prominent in the body of the epididymis than the head (caput) or tail (cauda) (Figure 3 ). Affected epithelial cells had no degenerative changes, and sperm density and morphology were unremarkable histologically.
Since the epididymis is an important site for sperm maturation, the potential effects of phospholipidosis on fertility were assessed by determining the number, morphology, and motility of sperm in the caudal epididymis of dogs given PNU-177864 for 4 weeks. Sperm number, morphology, and motility were comparable between control and treated dogs (Table 2 ). An identical evaluation of rat sperm could not be done because the mode of anesthesia (Isoflurane) had been demonstrated to interfere with sperm motility (unpublished observations).
Lymphocyte Vacuolation and Increased Serum CK and AST Are Potential Biomarkers for Clinical Monitoring
Phospholipidosis can be difficult to monitor clinically without the use of invasive methodology (i.e., biopsy). Some Vol. 32, No. 3, 2004 PHOSPHOLIPIDOSIS IN RAT AND DOG 331 CADs are known to produce phospholipidosis in peripheral blood lymphocytes of animals and man (Lullmann-Rauch, 1975; Dake et al., 1985) . To assess whether lymphocyte vacuolation was a potential biomarker for clinical studies with PNU-177864, peripheral blood smears were evaluated from rats and dogs given PNU-177864 for up to 4 weeks to determine if changes in lymphocyte morphology occurred with treatment. Lymphocytes from both rats and dogs given PNU-177864 had distinct cytoplasmic vacuoles (Figure 3 ) morphologically consistent with phospholipid accumulation. The vacuoles were clear, usually single, had distinct borders, and were 2-4 microns in diameter. Control animals did not have any lymphocyte vacuoles; monocytes from both controls and treated animals had small and multiple cytoplasmic vacuoles. Retrospectively, lymphocytes were examined from rats and dogs given PNU-177864 for 2 weeks. Lymphocyte vacuolation was observed in high-dose rats (200 mg/kg/day) euthanized after at least 1 week of dosing; however, lymphocyte vacuolation was not evident in dogs after 2 weeks of dosing. Myocyte degeneration and necrosis and cytoplasmic vacuolation occurred in all high-dose (200 mg/kg/day) rats in the 2-week study. Serum CK was increased in high dose females and AST was increased in both high-dose male and female rats and an individual female mid-dose rat (Table 3) . These analytes were considered potential safety biomarkers for skeletal muscle damage in clinical trials.
DISCUSSION
The structure of PNU-177864 (Figure 1 ) is consistent with a CAD and light microscopic and ultrastructural changes observed in rats and dogs given PNU-177864 were diagnostic for systemic phospholipidosis. Phospholipidosis occurs in almost any tissue and its tissue distribution can be quite different between animal species (Reasor, 1989; Halliwell, 1997) . PNU-177864 induced phospholipidosis in unusual target organs in dogs or rats including epididymis, pituitary, and hair 
88 (34) 2592 (188) a One female given 50 mg/kg/day had treatment-related elevations in CK and AST. b Mean U/ml and (standard deviations) from 2-week studies.
follicles. Literature reports of pituitary or hair follicle phospholipidosis were not identified and epididymal phospholipidosis is uncommon; only 1 literature report was found in the rat and the change is not reported in dogs (Yano, 2002) . Several potential explanations for differences in tissue distribution based on the CAD tested or species used for the preclinical testing are discussed extensively in reviews of phospholipidosis (Reasor, 1989; Halliwell, 1997) . Briefly, CADs may have different affinities for specific phospholipids that vary in their distribution in tissues and cell types among species. Chlorphentermine, a potent inducer of pulmonary phospholipidosis, binds phosphatidylcholine and charged polar lipids that are present at high concentrations in pulmonary surfactant and alveolar macrophages (Feldman et al., 1982; Reasor and Keyneman, 1983) . The disposition, metabolic, and clearance mechanisms may also be important for a CAD's ability to induce phospholipidosis in specific tissues. For example, gentamicin is excreted via the kidney where it concentrates in proximal tubule epithelial cells resulting in prominent renal phospholipidosis (Feldman et al., 1982) . Epididymal phospholipidosis was the principal change in dogs and also found in rats treated with PNU-177864. The body of the epididymis had more prominent changes; this has been our experience with other CADs that produce epididymal phospholipidosis (unpublished observations). Sperm enter the epididymis nonmotile and unable to fertilize the ovum. The epididymal epithelium secretes both proteins that prevent motility until after ejaculation and hormones (testosterones and estrogens), enzymes, and nutrients that may be important or essential for sperm maturation (Guyton et al., 1996) . While there was no morphologic evidence of epididymal epithelial cell degeneration and sperm density and morphology were unremarkable microscopically in both rats and dogs, further assessment of dog sperm was done to assist in the human risk assessment of the epididymal changes. There were no differences in sperm concentration, motility, and morphology between vehicle-treated and drug treated dogs, suggesting that the epididymal phospholipidosis observed in the dogs did not have an adverse effect on sperm maturation. If the development of PNU-177864 had continued, additional studies (i.e., rat fertility) would have been done to evaluate the potential effects of phospholipidosis on sperm function.
Phospholipidosis is sometimes associated with tissue injury in preclinical animal species and man; however, establishing a direct relationship between phospholipid accumulation and cell injury is difficult (Fardeau et al., 1979; Schmalbruch, 1980; Kumamato et al., 1989; Reasor, 1989; Halliwell, 1997; Yano, 2002) . For this reason, it is important that safety biomarkers are identified in preclinical studies for the clinical monitoring of patients. Two safety biomarkers were identified in preclinical studies with PNU-177864. Peripheral blood lymphocytes in both rats and dogs had changes consistent with phospholipidosis after 4 weeks of dosing. Peripheral blood lymphocyte phospholipidosis has been observed with other CADs and can be easily monitored in the clinic (Reasor, 1989; Halliwell, 1997) . Rats with skeletal myocyte degeneration had increased serum levels of CK and AST, both of which are monitored in clinical studies. Therefore, light microscopic and ultrastructural examination of peripheral blood lymphocytes and CK/AST monitoring were recommended as safety biomarkers for clinical trials. TOXICOLOGIC PATHOLOGY
The only indication of cellular injury that was associated with phospholipidosis in the preclinical studies with PNU-177864 was skeletal myocyte degeneration and necrosis in rats. The skeletal muscle changes and their risk assessment are discussed in detail in an accompanying manuscript (Vonderfecht et al., 2004) . While degenerate myocytes contained LLBs, these structures were frequently found in the absence of evidence of injury to the myocytes. Establishing a causal relationship between phospholipid accumulation and myocyte degeneration has been difficult (Fardeau et al., 1979; Schmalbruch, 1980; Kumamato et al., 1989) . The myocyte injury may be due to the more general membrane active nature of CADs instead of a direct result of phospholipidosis.
In summary, preclinical toxicology studies done in the rat and dog for PNU-177864 identified uncommon or unreported sites for phospholipidosis including epididymis, pituitary, and hair follicles. Changes were most prominent in the body of the epididymis of both species; however, the phospholipidosis was not associated with epididymal cell degeneration or quantitative or microscopic evidence of defects in sperm development. With the exception of skeletal muscle, there was no microscopic evidence of degenerative changes in organs with phospholipidosis changes. Peripheral lymphocyte vacuolation and increases in CK/AST were proposed as safety biomarkers for clinical testing of PNU-177864.
